INTERLEUKIN -23, APPLICATION PROSPECTS (LITERATURE REVIEW)
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
With the advent of new technologies, several new pro-inflammatory cytokines have been characterized, such as IL-23, which plays an important role in the pathogenesis of a number of inflammatory diseases. IL-23 pathways, as well as other proteins involved in the pathogenesis of inflammatory diseases, are currently under development and show promising efficacy and safety in early patient trials with minimal safety risks. Preliminary studies show that IL-23 therapy of the second generation is effective in the main inflammatory mechanisms.
Article Details
Как цитировать:
Библиографические ссылки:
Beketova T. V., Alexandrova E. N., Nikanorova N. O. Interleukin 23 in patients with systemic vasculitis associated with antineutrophil cytoplasmic antibodies: own results and literature review //Scientific and practical rheumatology. - 2015. – Vol. 53. – No. 5. – pp. 493-501
Barilo A.A., Smirnova S.V., Smolnikova M.V. Immunity indicators in patients with psoriatic arthritis depending on age // Medical Immunology, 2019. Vol. 21, No. 1. pp. 69-76.
Galushko E A, GordeevA V. Modern view on the pathogenesis of spondyloarthritis — molecular mechanisms. //Scientific and practical rheumatology. 2015;53(3):299-307
Gontar I. P. et al. Preparatory stage in pathogenetic treatment of psoriatic arthritis //Actual problems of modern rheumatology. – 2019. – pp. 50-56.
Ivanova E. Yu., Popova P. A. Experience of using interleukin-17 inhibitors in patients with psoriasis in outpatient practice //Topical issues of modern science and education. – 2022. – pp. 183-185.
Mingazheva E. T. et al. The role of polymorphic variants of immune response and inflammation genes in the pathogenesis of ovarian cancer in women of different ethnic origin //Medical genetics. – 2019. – Vol. 18. – No. 10. – pp. 10-20.
Nasonov E.L. New possibilities of pharmacotherapy of immuno-inflammatory rheumatic diseases: focus on interleukin 17 inhibitors // Scientific and practical rheumatology. 2017. No.1.P. -68-86
Novikov Yu. A. et al. Interleukins-23,-12P40 as markers of nerve tissue damage in neurosyphilis //Clinical laboratory diagnostics. – 2019. – Vol. 64. – No. 2. – pp. 94-97.
Novikov Yu.A., Indutny A.V., Kravchenko E.N. Immunological markers of nerve tissue damage as an element of a prognostic model of nervous system damage in syphilis // Clinical laboratory diagnostics. 2019. No.11. –pp.659-652
Smolnikova M. V. et al. Search for genetic markers of predisposition to psoriasis and psoriatic arthritis //Medical Immunology. – 2020. – Vol. 22. – No. 5. – pp. 925-932.
Abdo AIK, Tye GJ. Interleukin 23 and autoimmune diseases: current and possible future therapies. //Inflamm Res. 2020 May;69(5):463-480.
Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Molec Med. 2016;22:230-41.
Boch K, Langan EA, Kridin K, Zillikens D, Ludwig RJ, Bieber K. Lichen Planus. //Front Med (Lausanne). 2021 Nov 1;8:737813.
Bonifati C, Morrone A, Cristaudo A, Graceffa D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. //Dermatol Ther. 2021 Jan;34(1):e14584.
Chen L, He Z, Iuga AC. et al. Diet modifies colonic microbiota and CD4+ T-cell repertoire to induce flares of colitis in mice with myeloid-cell expression of interleukin 23.// Gastroenterology 2018;155:1177–91.e16.
Feagan BG, Sandborn WJ, D’Haens G. et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. //Lancet 2017;389:1699–709.
Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556–67; erratum: //Nat Rev Immunol 2009;9:747.
Griffiths C, Papp KA, Song M. et al. Maintenance of response through 5 years of continuous guselkumab treatment: results from the phase 3 VOYAGE 1 trial. Presented at the Coastal Dermatology Symposium Virtual Meeting Experience, 15–16 October 2020.
Infante-Duarte C, Horton HF, Byrne MC, Kamradt T.. Microbial lipopeptides induce the production of IL-17 in Th cells.// J Immunol 2000;165:6107–15.
Katayama H. Anti-interleukin-17A and anti-interleukin-23 antibodies may be effective against Alzheimer's disease: Role of neutrophils in the pathogenesis. //Brain Behav. 2020 Jan;10(1):e01504.
Li H, Tsokos GC. IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. //Clin Rev Allergy Immunol. 2021 Feb;60(1):31-45.
Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, Qiao J, Fang H. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. //Front Immunol. 2020 Nov 17;11:594735.
Lucaciu LA, Ilieș M, Vesa ȘC, Seicean R, Din S, Iuga CA, Seicean A. Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease. //J Pers Med. 2021 Nov 2;11(11):1130.
Mardani M, Mofidi H, Dastgheib L, Ranjbar S, Hamidizadeh N. Elevated Serum Interleukin-23 Levels in Patients with Oral and Cutaneous Lichen Planus. //Mediators Inflamm. 2021 Jul 12;2021:5578568.
Markota Čagalj A, Marinović B, Bukvić Mokos Z. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. //Int J Mol Sci. 2022 Mar 29;23(7):3753.
Miossec P, Kolls JK (2012) Нацеливание на клетки IL-17 и TH17 при хроническом воспалении. //Nat Rev Drug Discov – 2012.-11 ( 10 ): 763–776.
Sandborn WJ, Ferrante M, Bhandari BR. et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. //Gastroenterology 2020;158:537–49.e10.